
Oncology NEWS International
- Oncology NEWS International Vol 11 No 12
- Volume 11
- Issue 12
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
FRAMINGHAM, Massachusetts-Genzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.
FRAMINGHAM, MassachusettsGenzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.
According to Genzyme, the cell fusion technology eliminates the need to identify specific tumor proteins because the technique uses the entire tumor cell to provide targets for the immune system to attack.
Articles in this issue
over 23 years ago
Stereotactic Radiosurgery Benefits Brain Met Patientsover 23 years ago
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Reportover 23 years ago
Tailored Messages Motivate Women to Get Mammogramsover 23 years ago
Chemo/Rituximab Is Effective as First-Line CLL Therapyover 23 years ago
Preoperative Capecitabine/RT Downstages Rectal Cancerover 23 years ago
Intraoperative Lymphatic Mapping Enhances Cancer Stagingover 23 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLover 23 years ago
Lower Breast Cancer Survival in Hispanics: New Mexico Studyover 23 years ago
Concurrent Chemo/RT More Likely to Save LarynxNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.






















































